PetVivo Holdings Inc (PETV) Peer Comparison
$0.68
$-0.44
(-39.43%)
As on 03-Sep-2026 16:00EDT
Market cap
$26 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
19.1
Div. Yield
0 %
Edit
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
26 | 12,753 | 10,906 | 9,762 | 9,948 |
Revenue ($ Mln) |
1 | 1,505 | 613 | 2,589 | 785 |
Net Profit ($ Mln) |
-9.78 | 160.59 | -188.05 | 222.40 | 41.54 |
Net Margin (%) |
-827.34 | 10.67 | -30.68 | 8.59 | 5.29 |
RoE (%) |
-412.95 | 10.86 | -28.10 | 3.04 | 1.97 |
Price to Earnings |
-- | 79.35 | -- | 44.47 | 251.81 |
Price-To-Book |
19.10 | 8.41 | 16.38 | 1.26 | 4.86 |
Income Statement ($ Mln)
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1.14 | 1,403.67 | 507.44 | 2,583.20 | 738.26 |
|
Cost of Revenue
|
0.39 | 461.23 | 114.23 | 1,239.60 | 390.63 |
|
Gross Profit
|
0.75 | 942.44 | 393.22 | 1,343.60 | 347.62 |
|
Operating Expenses
|
8.82 | 753.19 | 479.95 | 1,077.50 | 288.05 |
|
Operating Profit (EBIT)
|
-8.06 | 189.25 | -86.73 | 270.50 | 59.58 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-10.47 | 205.13 | -193.04 | 995.50 | 62.38 |
|
Provision for Tax
|
-- | 27.44 | -5.35 | 235.60 | 13.49 |
|
Profit after Tax (Net Income)
|
-10.47 | 177.69 | -187.69 | 759.90 | 48.89 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | 177.69 | -- | -- | -- |
Liabilities ($ Mln)
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2.20 | 1,427.60 | 656.16 | 7,453.60 | 2,106.13 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 215.78 | 136.06 | 2,605.90 | 707.74 |
|
Current Liabilities
|
1.38 | 183.13 | 101.28 | 517.00 | 135.83 |
|
Total Liabilities
|
3.58 | 1,826.52 | 893.49 | 10,576.50 | 2,949.70 |
Assets ($ Mln)
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1.72 | 609.84 | 418.50 | 7,670.30 | 1,812.31 |
|
Current Assets
|
1.86 | 1,216.68 | 474.98 | 2,906.20 | 1,137.39 |
|
Total Assets
|
3.58 | 1,826.52 | 893.49 | 10,576.50 | 2,949.70 |
|
Total Debt*
|
0.38 | 219.70 | 139.64 | 1,531.00 | 689.95 |
|
Net Current Assets
|
0.48 | 1,033.55 | 373.71 | 2,389.20 | 1,001.56 |
Cashflow ($ Mln)
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-6.11 | 238.66 | -46.34 | 532.20 | 117.42 |
|
Cash Flow from Investing Activities
|
0.01 | -404.59 | -77.61 | -189.70 | -298.47 |
|
Cash from Financing Activities
|
6.07 | 26.53 | 11.89 | -283.20 | -15.21 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-216.02 | 11.76 | -22.53 | 8.98 | 1.79 |
|
ROE (%)
|
-326.35 | 13.78 | -26.38 | 10.84 | 2.40 |
|
ROA (%)
|
-162.18 | 10.58 | -20.09 | 7.62 | 1.69 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-917.45 | 12.66 | -36.99 | 29.42 | 6.62 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.01 | 0.17 | 0.32 | 0.01 | 0.16 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-24.70 | 1,168.11 | -28.23 | 141.20 | 291.64 |
|
EPS Growth (%)
|
0.14 | 11.64 | -0.24 | 1.43 | 2.90 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.71 | 68.93 | -34.59 | -- | 189.42 |
|
Price / Book Value
|
3.40 | 8.58 | 9.90 | -- | 4.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-2.20 | 53.25 | -43.50 | -- | 55.90 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.17 | 0.15 | 0.21 | 0.21 | 0.33 |
|
Short term debt to equity ratio
|
0.17 | 0.01 | -- | 0.01 | 0.01 |
|
Current Ratio
|
1.35 | 6.64 | 4.69 | 5.62 | 8.37 |
|
Quick Ratio
|
0.96 | 4.29 | 4.06 | 4.19 | 7.12 |
|
Interest Coverage
|
-8.83 | 157.46 | -40.65 | 21.32 | 3.69 |
Operating Efficiency Ratios
| PetVivo Holdings Inc (PETV) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
61.39 | 13.54 | 21.40 | 18.29 | 21.48 |
|
Asset Turnover
|
0.18 | 0.84 | 0.54 | 0.26 | 0.26 |
|
Receivable days
|
825.68 | 46.54 | 60.95 | 65.39 | 72.41 |
|
Inventory Days
|
406.87 | 331.92 | 193.84 | 221.09 | 146.53 |
|
Payable days
|
646.04 | 26.16 | 60.19 | 37.02 | 29.05 |
|
Cash Conversion Cycle
|
586.51 | 352.30 | 194.60 | 249.46 | 189.88 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
